<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(2)</volume><submitter>Kim YK</submitter><pubmed_abstract>This study aimed to control rapid localized corrosion and inflammation of biodegradable magnesium implants by developing a pH-responsive mPEG-PLGA coating loaded with dexamethasone (Dex). The mPEG-PLGA layer was designed to selectively degrade in alkaline conditions, thereby moderating pH elevation at the implant surface while enabling controlled Dex release. By varying the molecular weight of mPEG and PLGA, the degradation rate and microsphere size were tunable, allowing adjustment of the drug release profile. Among the tested coating solution concentrations (1.5-7.5 mg/mL), the formulation with 3 mg/mL Dex yielded a final cumulative release concentration of 0.02 mg/mL over a two-week period, which suppressed inflammatory responses in RAW 264.7 macrophages with minimal cytotoxicity, while</pubmed_abstract><journal>Polymers</journal><pagination>303</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12846112</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>pH-Responsive mPEG-PLGA/Dexamethasone Coatings for Corrosion Control and Osteo-Immune Modulation of Biodegradable Magnesium.</pubmed_title><pmcid>PMC12846112</pmcid><pubmed_authors>Lee MH</pubmed_authors><pubmed_authors>Kim SY</pubmed_authors><pubmed_authors>Kim YK</pubmed_authors><pubmed_authors>Jang YS</pubmed_authors></additional><is_claimable>false</is_claimable><name>pH-Responsive mPEG-PLGA/Dexamethasone Coatings for Corrosion Control and Osteo-Immune Modulation of Biodegradable Magnesium.</name><description>This study aimed to control rapid localized corrosion and inflammation of biodegradable magnesium implants by developing a pH-responsive mPEG-PLGA coating loaded with dexamethasone (Dex). The mPEG-PLGA layer was designed to selectively degrade in alkaline conditions, thereby moderating pH elevation at the implant surface while enabling controlled Dex release. By varying the molecular weight of mPEG and PLGA, the degradation rate and microsphere size were tunable, allowing adjustment of the drug release profile. Among the tested coating solution concentrations (1.5-7.5 mg/mL), the formulation with 3 mg/mL Dex yielded a final cumulative release concentration of 0.02 mg/mL over a two-week period, which suppressed inflammatory responses in RAW 264.7 macrophages with minimal cytotoxicity, while</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-16T03:18:31.565Z</modification><creation>2026-06-16T03:09:56.09Z</creation></dates><accession>S-EPMC12846112</accession><cross_references><pubmed>41599597</pubmed><doi>10.3390/polym18020303</doi></cross_references></HashMap>